Showing results (111-120 of 148) with videos related to
Sort By:
Pageof 15
Journal of Crohn'S & Colitis|November 2, 2022
Post-inflammatory Polyp Burden as a Prognostic Marker of Disease-outcome in Patients with Inflammatory Bowel DiseasePierre Ellul, John Schembri, Andrea Vella Baldacchino, et al.Ebiomedicine|January 12, 2023
The gut microbiota and metabolome are associated with diminished COVID-19 vaccine-induced antibody responses in immunosuppressed inflammatory bowel disease patientsJames L Alexander, Benjamin H Mullish, Nathan P Danckert, et al.BMJ Open Gastroenterology|February 9, 2024
Determining the optimal treatment target in patients with ulcerative colitis: rationale, design, protocol and interim analysis for the randomised controlled VERDICT trialVipul Jairath, Guangyong Zou, Zhongya Wang, et al.Alimentary Pharmacology & Therapeutics|June 23, 2025
Clinical Utility and Cost-Effectiveness of Pretreatment NUDT15 Pharmacogenetic Testing to Prevent Thiopurine-Induced Myelosuppression: A Genotype-First Reverse Phenotyping Cohort Study Within the UK NIHR Inflammatory Bowel Disease BioresourceChristopher Roberts, Jaime Peters, Aleksejs Sazonvos, et al.The Lancet. Gastroenterology & Hepatology|March 3, 2019
Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort studyNicholas A Kennedy, Graham A Heap, Harry D Green, et al.Journal of Crohn'S & Colitis|June 3, 2025
Long-term disease course of ulcerative colitis in a prospective European population-based inception cohort-an Epi-IBD cohort studyMads Damsgaard Wewer, Søren Lophaven, Peter L Lakatos, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 5, 2025
Long-term Disease Course of Crohn's Disease in a Prospective European Population-based Inception Cohort: An Epi-IBD Cohort StudyMads Damsgaard Wewer, Søren Lophaven, Peter L Lakatos, et al.The Lancet. Gastroenterology & Hepatology|February 6, 2022
COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control studyJames L Alexander, Nicholas A Kennedy, Hajir Ibraheim, et al.Alimentary Pharmacology & Therapeutics|May 16, 2020
Effectiveness of ustekinumab dose escalation in Crohn's disease patients with insufficient response to standard-dose subcutaneous maintenance therapyUri Kopylov, Jurij Hanzel, Claire Liefferinckx, et al.Journal of Crohn'S & Colitis|September 19, 2025
International consensus on the use of intestinal ultrasound in inflammatory bowel disease trialsMariangela Allocca, Vipul Jairath, Bruce E Sands, et al.Pageof 15